HK1105963A1 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners - Google Patents
Compounds and methods for inhibiting the interaction of bcl proteins with binding partnersInfo
- Publication number
- HK1105963A1 HK1105963A1 HK07111188.2A HK07111188A HK1105963A1 HK 1105963 A1 HK1105963 A1 HK 1105963A1 HK 07111188 A HK07111188 A HK 07111188A HK 1105963 A1 HK1105963 A1 HK 1105963A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- inhibiting
- interaction
- methods
- binding partners
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58061604P | 2004-06-17 | 2004-06-17 | |
US65930105P | 2005-03-07 | 2005-03-07 | |
PCT/US2005/021524 WO2006009869A1 (en) | 2004-06-17 | 2005-06-17 | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1105963A1 true HK1105963A1 (en) | 2008-02-29 |
Family
ID=35335774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07111188.2A HK1105963A1 (en) | 2004-06-17 | 2007-10-17 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Country Status (22)
Country | Link |
---|---|
US (1) | US7851637B2 (ja) |
EP (1) | EP1768966B1 (ja) |
JP (1) | JP5064213B2 (ja) |
KR (1) | KR101195351B1 (ja) |
CN (1) | CN101006065B (ja) |
AT (1) | ATE548359T1 (ja) |
AU (1) | AU2005265131B2 (ja) |
BR (1) | BRPI0511070A (ja) |
CA (1) | CA2570780C (ja) |
EC (1) | ECSP067099A (ja) |
ES (1) | ES2382383T3 (ja) |
HK (1) | HK1105963A1 (ja) |
IL (1) | IL179904A (ja) |
MA (1) | MA28702B1 (ja) |
MX (1) | MXPA06014754A (ja) |
NO (1) | NO20070324L (ja) |
NZ (1) | NZ552183A (ja) |
PL (1) | PL1768966T3 (ja) |
PT (1) | PT1768966E (ja) |
RU (1) | RU2416606C2 (ja) |
WO (1) | WO2006009869A1 (ja) |
ZA (1) | ZA200610405B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
EP1768966B1 (en) | 2004-06-17 | 2012-03-07 | Infinity Discovery, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
EP1897956A1 (en) | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
DE112009000300T5 (de) * | 2008-02-08 | 2011-01-20 | Aileron Therapeutics, Inc., Cambridge | Therapeutische Peptidomimetische Makrocyclen |
US20110086834A1 (en) * | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
WO2010021752A1 (en) | 2008-08-21 | 2010-02-25 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI600652B (zh) * | 2008-12-05 | 2017-10-01 | 艾伯維有限公司 | 用於治療癌症及免疫疾病之bcl-2-選擇性細胞凋亡誘發劑 |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
CN104906100A (zh) * | 2009-05-26 | 2015-09-16 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8314250B2 (en) | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
CN106163557B (zh) | 2014-01-28 | 2020-07-14 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN108602809B (zh) * | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
RU2020121147A (ru) | 2016-03-28 | 2021-11-03 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS55133364A (en) * | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
DE3643012A1 (de) * | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
DE3829594A1 (de) * | 1988-09-01 | 1990-03-15 | Bayer Ag | Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
DE3926822A1 (de) * | 1989-08-14 | 1991-02-21 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
JPH09505590A (ja) * | 1993-11-24 | 1997-06-03 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | 新規なイソオキサゾリンおよびイソオキサゾールフィブリノーゲン受容体拮抗剤 |
DK0730587T3 (da) * | 1993-11-26 | 2000-04-10 | Pfizer | 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler |
CA2185019C (en) | 1994-03-09 | 2000-08-08 | Pfizer Limited | Isoxazoline compounds as inhibitors of tnf release |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
IT1283836B1 (it) | 1996-08-28 | 1998-04-30 | Viv Int Spa | Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura |
WO1998016830A2 (en) | 1996-10-16 | 1998-04-23 | The President And Fellows Of Harvard College | Droplet assay system |
AR015649A1 (es) * | 1997-05-07 | 2001-05-16 | Univ Pittsburgh | Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento |
AU7105800A (en) | 1999-09-01 | 2001-03-26 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
JP2005515158A (ja) | 2001-05-30 | 2005-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Blc−2ファミリータンパク質の小分子アンタゴニスト |
US20030119894A1 (en) * | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
EP1768966B1 (en) | 2004-06-17 | 2012-03-07 | Infinity Discovery, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
-
2005
- 2005-06-17 EP EP05762701A patent/EP1768966B1/en active Active
- 2005-06-17 JP JP2007516793A patent/JP5064213B2/ja not_active Expired - Fee Related
- 2005-06-17 KR KR1020077001087A patent/KR101195351B1/ko not_active IP Right Cessation
- 2005-06-17 NZ NZ552183A patent/NZ552183A/en not_active IP Right Cessation
- 2005-06-17 WO PCT/US2005/021524 patent/WO2006009869A1/en active Application Filing
- 2005-06-17 US US11/156,364 patent/US7851637B2/en not_active Expired - Fee Related
- 2005-06-17 AT AT05762701T patent/ATE548359T1/de active
- 2005-06-17 CA CA2570780A patent/CA2570780C/en not_active Expired - Fee Related
- 2005-06-17 ES ES05762701T patent/ES2382383T3/es active Active
- 2005-06-17 CN CN2005800281288A patent/CN101006065B/zh not_active Expired - Fee Related
- 2005-06-17 MX MXPA06014754A patent/MXPA06014754A/es active IP Right Grant
- 2005-06-17 RU RU2007101276/04A patent/RU2416606C2/ru not_active IP Right Cessation
- 2005-06-17 AU AU2005265131A patent/AU2005265131B2/en not_active Ceased
- 2005-06-17 PT PT05762701T patent/PT1768966E/pt unknown
- 2005-06-17 BR BRPI0511070-0A patent/BRPI0511070A/pt active Search and Examination
- 2005-06-17 PL PL05762701T patent/PL1768966T3/pl unknown
-
2006
- 2006-12-07 IL IL179904A patent/IL179904A/en not_active IP Right Cessation
- 2006-12-12 ZA ZA200610405A patent/ZA200610405B/en unknown
- 2006-12-20 EC EC2006007099A patent/ECSP067099A/es unknown
- 2006-12-29 MA MA29588A patent/MA28702B1/fr unknown
-
2007
- 2007-01-17 NO NO20070324A patent/NO20070324L/no not_active Application Discontinuation
- 2007-10-17 HK HK07111188.2A patent/HK1105963A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ECSP067099A (es) | 2007-04-26 |
CN101006065A (zh) | 2007-07-25 |
AU2005265131A1 (en) | 2006-01-26 |
IL179904A0 (en) | 2007-05-15 |
JP5064213B2 (ja) | 2012-10-31 |
JP2008503489A (ja) | 2008-02-07 |
PT1768966E (pt) | 2012-05-23 |
KR20070046068A (ko) | 2007-05-02 |
RU2416606C2 (ru) | 2011-04-20 |
RU2007101276A (ru) | 2008-08-10 |
KR101195351B1 (ko) | 2012-10-29 |
CA2570780C (en) | 2013-12-03 |
CA2570780A1 (en) | 2006-01-26 |
WO2006009869A1 (en) | 2006-01-26 |
PL1768966T3 (pl) | 2012-08-31 |
EP1768966A1 (en) | 2007-04-04 |
US20060025460A1 (en) | 2006-02-02 |
AU2005265131B2 (en) | 2012-02-23 |
NO20070324L (no) | 2007-03-19 |
NZ552183A (en) | 2009-10-30 |
MXPA06014754A (es) | 2007-06-22 |
BRPI0511070A (pt) | 2007-11-27 |
CN101006065B (zh) | 2012-07-11 |
ES2382383T3 (es) | 2012-06-07 |
EP1768966B1 (en) | 2012-03-07 |
US7851637B2 (en) | 2010-12-14 |
IL179904A (en) | 2011-11-30 |
ZA200610405B (en) | 2008-03-26 |
MA28702B1 (fr) | 2007-06-01 |
ATE548359T1 (de) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL179904A0 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
MX2009005184A (es) | Compuestos y metodos para inhibir la interaccion de las proteinas bcl con agentes aglutinantes. | |
JO2917B1 (en) | Compounds and methods to inhibit the interaction between BCL and binding partners | |
TNSN08258A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
TW200716624A (en) | Compounds for modulating TRPV3 function | |
WO2007139960A3 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
WO2007094819A8 (en) | Triazole compounds that modulate hsp90 activity | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
HK1107700A1 (en) | Triazole compounds that modulate hsp90 activity | |
MX2007011859A (es) | Compuestos mejorados farmacocineticamente. | |
SG171682A1 (en) | Iap bir domain binding compounds | |
TW200640924A (en) | VEGF-R2 inhibitors and methods | |
TW200738683A (en) | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | |
TN2010000169A1 (en) | Molecules and methods for modulating complement component | |
WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
TW200745159A (en) | IL-6 binding proteins | |
WO2003084475A3 (en) | INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME | |
WO2004060878A3 (en) | Inhibitors of phosphatases | |
TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
TW200621265A (en) | Composition for treating tumor and/or preventing tumor transfer and recurrence | |
UA115859C2 (uk) | Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить | |
TW200800952A (en) | Biaryl compositions and methods for modulating a kinase cascade | |
CY1115478T1 (el) | Ενωσεις τριαζολης που διαμορφωνουν δραση ηsρ90 | |
UA98927C2 (ru) | Антитело или его фрагмент, которое связывается со склеростином |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160617 |